Clinical Trial Update: A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Rozanolixizumab in adults with Generalized Myasthenia Gravis has completed, and the study results were posted on 2025-04-18.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Rozanolixizumab

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Generalized Myasthenia Gravis | Phase 3 | Status: COMPLETED | Results posted: 2025-04-18